ESfEQA
European Society for External Quality Assessment

Survey for Blood Grouping (ABO)

EQA Provider:	ESfEQA GmbH Heidelberg
ESfEQA Head of Operations:	Dr. D. Groche

Instructions for Use

Notes:

Potentially Biohazardous Material. The human blood donations used for manufacturing the controls were found to be non-reactive for HBsAg, anti-HIV 1/2 and anti-HCV. The usual precautions in the laboratory for handling potentially hazardous samples apply for these controls. The controls should be used by trained personnel only.

This product contains human source material and should be considered as potentially infectious.

Various tasks of the proficiency testing scheme may occasionally be given over to qualified subcontractors. However, ESfEQA is responsible to the participants for the subcontractor's work.

Results from sample analysis may only be disclosed to colleagues from other laboratories after the testing period has been concluded.

By registering for and participating in this EQA participants agree to accept the general terms and conditions of ESfEQA GmbH. These can be retrieved online at www.esfeqa.eu

1. Intended Use

The samples are intended for use as qualitative control material for External Quality Assessment (EQA) in medical laboratories for the following analysis:

ABO-Typing
Rhesus (D) antigen detection

2. Product Description

The samples are suspensions of human erythrocytes that contain a red blood cell concentration of 8% in a buffer with preservatives. The samples are ready to use.

Sample 1: ABO_2022_04_a
Sample 2: ABO_2022_04_b

3. Storage and Stability

The samples should be stored upright at 2-8 °C. They are stable at least until the deadline for data submission as indicated below.

4. Sample Preparation and Analysis

All samples should be treated the same way as patient samples and analyzed in accordance with the instructions of the instrument and reagent manufacturer.

In detail, prior to use gently agitate the vial until the sedimented blood cells have been completely suspended. Occasionally invert the vial, but do not shake the sample. Continue to gently agitate the sample until the blood cells have been completely suspended.

Do not mix the sample on a mechanical analyzer.

Directly before use, gently invert the tube another 8-10 times.

Incomplete mixing of a vial prior to use may invalidate both the sample withdrawn and any remaining material in the vial.

5. Dates and Submission of Test Results

Testing Period for Samples 1 and 2: 17/10/22 - 07/11/22

Please submit your results electronically to ESfEQA at https://teqa.esfeqa.eu.

Contact your local distributor of ESfEQA programs or ESfEQA directly if you need assistance with registration in TEQA. Alternatively, though not preferred, use the fax form provided on the ESfEQA website. In both cases indicate the instrument and method used for the analysis of the samples.

6. Deadline for Data Submission

Deadline for data submission (time zone GMT +1):

Samples 1 and 2: 07/11/22

7. Reports and Certificates

The data will be evaluated by ESfEQA. The individual laboratory reports and certificates can be retrieved online at https://teqa.esfeqa.eu. The reports and certificates will be available within 3 weeks after the deadline of data submission.

ESfEQA GmbH
Siemensstr. 38
69123 Heidelberg
Germany

Phone: + 49 6221 4166-700
Fax: + 49 6221 4166-790
info@esfeqa.eu
www.esfeqa.eu